Posts by: Marisa Wexler, MS

Marisa Wexler, MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

September 14, 2020September 14, 2020

Phase 3 Trial of AXS-05 to Treat Agitation in Alzheimer’s Likely by Year’s End

News

Axsome Therapeutics announced plan to soon open a Phase 3 clinical trial of AXS-05, its investigational oral treatment for Alzheimer’s disease-related agitation, after U.S. Food and Drug Administration (FDA) officials confirmed ... Read more

August 26, 2020August 26, 2020

Patients in Australian Trials of Anavex 2-73 May Continue Using Therapy, Agency Says

News

People in Australia with Alzheimer’s disease who have finished five years of treatment with Anavex 2-73 (blarcamesine) in Phase 2 clinical trials may continue to use Anavex Life Sciences‘ investigational oral therapy at ... Read more

June 3, 2020June 3, 2020

Mouth Bacteria Can Infect Brain Cells, Research Finds, Supporting Alzheimer’s Link

News

A type of mouth bacteria involved in gum disease is able to infect human brain cells, new research shows. The infection results in cellular changes that are similar to ... Read more

May 18, 2020May 18, 2020

PTI-125 Fails to Lower Alzheimer’s Protein Levels in Phase 2 Trial

News

Cassava Sciences‘s investigational therapy PTI-125 failed to significantly lower the levels of Alzheimer’s-relevant biomarkers present in fluid surrounding the brain and spinal cord of patients, according to results from ... Read more

May 4, 2020May 4, 2020

Large Study Finds No Evidence That Low-dose Aspirin Reduces Alzheimer’s Risk

News

Taking daily low-dose aspirin does not seem to reduce the risk of dementia, cognitive decline, or Alzheimer’s disease, new clinical trial data show. The results were published in Neurology in a ... Read more

April 13, 2020May 14, 2020

Phase 2/3 Trial of Treatment for Agitation in Alzheimer’s to Conclude Early

News

Axsome Therapeutics is planning to complete its ADVANCE-1 clinical trial, evaluating AXS-05 as a treatment for agitation in Alzheimer’s disease, a few months earlier to ensure the safety of study ... Read more

January 17, 2020January 17, 2020

Biogen Acquiring Pfizer’s Investigational Therapy PF-05251749 for Alzheimer’s, Parkinson’s Symptoms

News

Biogen is acquiring from Pfizer investigational therapy PF-05251749, a small molecule being developed to treat sundowning in Alzheimer’s disease and irregular sleep wake rhythm disorder (ISWRD) in Parkinson’s disease. The ... Read more

December 6, 2019December 6, 2019

Repeat Coding in Gene Region Linked to Risk of Late-onset Alzheimer’s, Study Suggests

News

Longer sequence repeats in or near two genes may be linked to a higher risk of late-onset Alzheimer’s disease, a study reports. The study “Alzheimer Disease Pathology-Associated Polymorphism in ... Read more

November 26, 2019November 26, 2019

Phase 2 Trial to Test New Way of Measuring Tau Plaques in Living Brains

News

A newly opened Phase 2 clinical trial will test the sensitivity of new imaging tool for plaque buildup in the brains of people with mild cognitive impairment and dementia ... Read more

November 4, 2019November 4, 2019

High-salt Diet can Cause Dementia by Promoting Accumulation of Tau Plaques, Mouse Study Says

News

A diet that is high in salt can cause dementia in mice by promoting a buildup of plaques of the protein tau, which is also associated with Alzheimer’s disease, ... Read more

Pin It on Pinterest